Which feature best distinguishes tyrosine kinase inhibitors (TKIs) from monoclonal antibodies in targeted cancer therapy?

Explanation

## Distinguishing Features of TKIs vs Monoclonal Antibodies **Key Point:** The fundamental discriminator between TKIs and monoclonal antibodies lies in their site of action and route of delivery. ### Structural and Pharmacokinetic Differences | Feature | TKIs | Monoclonal Antibodies | |---------|------|----------------------| | **Molecular size** | Small molecules (300–500 Da) | Large proteins (150 kDa) | | **Site of action** | Intracellular (cytoplasm/nucleus) | Extracellular (cell surface receptors) | | **BBB penetration** | Excellent (lipophilic, small) | Poor (large, hydrophilic) | | **Route of administration** | Oral (most) | Intravenous | | **Mechanism of cell death** | Apoptosis via kinase inhibition | ADCC, CDC, direct receptor blockade | | **Selectivity** | Often multi-target (off-target effects) | Highly specific to single antigen | ### Why TKIs Cross the Blood-Brain Brain Barrier **High-Yield:** TKIs are small, lipophilic molecules that readily cross the BBB via passive diffusion. This allows treatment of CNS metastases (e.g., erlotinib in brain metastases from EGFR-mutant lung cancer). Monoclonal antibodies, being large hydrophilic proteins, cannot cross an intact BBB and are therefore ineffective for CNS disease. **Clinical Pearl:** This distinction is clinically critical — a patient with EGFR-mutant NSCLC and brain metastases would benefit from a TKI (e.g., gefitinib, erlotinib) over a monoclonal antibody (e.g., cetuximab), precisely because the TKI achieves therapeutic CNS concentrations. ### Mechanism of Action Comparison **Monoclonal antibodies** exert their anti-tumor effect primarily through: - ADCC (antibody-dependent cellular cytotoxicity) - CDC (complement-dependent cytotoxicity) - Direct receptor antagonism (e.g., trastuzumab blocking HER2) **TKIs** work by: - Competitive inhibition of ATP binding to the kinase domain - Blocking downstream signaling (MAPK, PI3K/AKT pathways) - Inducing apoptosis in kinase-dependent cells **Mnemonic:** **SMALL = Soluble, Membrane-acting, Antibodies; Large = Lipophilic, Intracellular, Kinase-inhibitors** (inverted, but captures the contrast).